Nemes Rush Group’s TG Therapeutics TGTX Stock Holding History

Nemes Rush Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$110K	Sell	2,000 -19	-0.9%	-$778	0.01%	278
2026 Q1	$67.1K	Hold	2,019	–	–	0.01%	313
2025 Q4	$60.2K	Hold	2,019	–	–	0.01%	324
2025 Q3	$72.9K	Hold	2,019	–	–	0.01%	284
2025 Q2	$72.7K	Hold	2,019	–	–	0.01%	279
2025 Q1	$79.6K	Buy	2,019 +19	+1%	+$639	0.01%	273
2024 Q4	$60.2K	Hold	2,000	–	–	0.01%	284
2024 Q3	$30.4K	Hold	2,000	–	–	﹤0.01%	310
2024 Q2	$35.6K	Hold	2,000	–	–	﹤0.01%	294
2024 Q1	$30.4K	Hold	2,000	–	–	﹤0.01%	337
2023 Q4	$34.2K	Hold	2,000	–	–	0.01%	304
2023 Q3	$16.7K	Hold	2,000	–	–	﹤0.01%	352
2023 Q2	$49.7K	Buy	+2,000	New	+$51.7K	0.01%	264

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Nemes Rush Group's TGTX Position: Q2 2026 in Review

Nemes Rush Group reduced its TG Therapeutics (TGTX) stake by 0.94% in Q2 2026, selling an estimated $778 and leaving 2,000 shares worth $110K. The position accounts for 0.01% of the portfolio, ranked #278.

Nemes Rush Group first reported a position in TGTX in Q2 2023 and has held it in 13 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Nemes Rush Group held 2,000 shares of TG Therapeutics worth $110K as of Q2 2026.
Nemes Rush Group sold 19 TG Therapeutics shares in Q2 2026, an estimated $778.
TG Therapeutics made up 0.01% of Nemes Rush Group's portfolio in Q2 2026, its #278 holding.
Nemes Rush Group first reported a position in TG Therapeutics in Q2 2023 and has held it in 13 quarters since.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.